Maxim Group Reiterates “$11.00” Price Target for AEterna Zentaris Inc. (AEZS)
Maxim Group set a $11.00 price objective on AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) in a research note published on Thursday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
“Zoptrex pivotal Phase 3 trial was completed on January 30, 2017. A pre-NDA meeting with FDA heldthe next day. Top-line results expected to be reported in April 2017.”,” the firm’s analyst commented.
Other equities analysts have also recently issued reports about the company. HC Wainwright reissued a buy rating and set a $7.50 target price (down from $12.00) on shares of AEterna Zentaris in a research note on Tuesday, January 10th. Zacks Investment Research raised AEterna Zentaris from a sell rating to a buy rating and set a $3.00 target price on the stock in a research note on Tuesday, January 10th. Finally, Canaccord Genuity set a $6.00 target price on AEterna Zentaris and gave the company a buy rating in a research note on Sunday, January 8th.
AEterna Zentaris (NASDAQ:AEZS) opened at 2.90 on Thursday. AEterna Zentaris has a 52 week low of $2.35 and a 52 week high of $5.59. The firm’s 50-day moving average price is $3.04 and its 200 day moving average price is $3.40. The company’s market capitalization is $33.84 million.
AEterna Zentaris (NASDAQ:AEZS) last posted its earnings results on Wednesday, March 15th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.02. AEterna Zentaris had a negative return on equity of 213.27% and a negative net margin of 3,773.91%. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.40 million. During the same period in the previous year, the firm earned ($1.46) earnings per share. The business’s revenue was up 200.0% compared to the same quarter last year. Equities research analysts expect that AEterna Zentaris will post ($1.43) earnings per share for the current fiscal year.
Your IP Address:
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.